Sunday August 20th 2017

Going abroad for Lemtrada for MS is reminiscent of CCSVI

LemtradaThere are many who suffer from multiple sclerosis (MS) in the United States who are upset with the FDA for not approving of the drug Alemtuzumab, otherwise known as Lemtrada.

To the point where a petition was made to fight the ruling.

This, on top of Genzyme appealing the ruling, it looks like it is going to be an on-going issue for the MS community and some have been looking into going to other countries to receive the treatments; a bit like what some patients have done for chronic cerebrospinal venous insufficiency (CCSVI) just a couple years ago.

Other countries, like Canada and those in the E.U., have approved Lemtrada for a therapy but the United States is digging in its heals.

When used for therapy for those with MS, the medication is administered over a five-day period. This is followed by a three-day course one year later with a final dose in the third year and has been in the news off and on these last two years due to many issues.

One being last month’s class action suit brought by Lieff Cabraser Heimann and Berstein, LLP stating there were “misleading statements on the safety and efficacy of the multiple sclerosis drug Lemtrada.” They filed on behalf of those who had purchased contingent value rights (CVRs) from Sanofi.

Sanofi is a global pharmaceutical group that deals in research and development, manufacturing and marketing of healthcare products and they had bought Genzyme a few years ago.

It was with the purchase of Genzyme where Lemtrada came into play because the drug came with it and shareholders received CVRs that were linked to Lemtrada’s future success.

[Get free email subscription to Lima Multiple Sclerosis Examiner to receive news and updates [click here].

Most studies are usually double-blind, meaning those who administer the actual drug and those who are receiving it typically do not know what is the placebo and which is not; and the lawyers pointed out the Lemtrada study was not handled this way.

There are lawyers on top of doctors on top of those in the FDA who have all pointed out the same thing: no double blind is an issue.

This may not have been an issue with the lawyers but for doctors there is also the safety issue: six trial participants developing thyroid cancer, three were diagnosed with melanoma and five deaths that were possibly related to the treatment (the other three deaths were considered unrelated) along with the infusion reactions.

This drug may be found to be too costly for the manufacturers to try to keep alive here in the U.S. Especially if the appeal doesn’t succeed.

It had been noted that doctors “could provide off-label prescriptions and give patients Campath”, but this isn’t going to be a viable action as Sanofi is already twenty steps ahead of this.

They pulled Campath off the U.S. and E.U. markets and renamed it Lemtrada. They were that confident that their non-double-blind studies were going to garner them success.

Well, that and Campath’s treatment for B cell chronic lymphocytic leukemia sales had been “declining for some years” anyway so the money grabber would’ve been with this disease anyway.

It looks as if the other ‘option’, the traveling out of the country, is going to be the only option because fighting MS along-side Gilenya and Tecfidera may end up being too costly.


Read More

Leave a Comment

More from category

Queensland doctors find therapy to halt progression of M.S.
Queensland doctors find therapy to halt progression of M.S.

BRISBANE researchers believe they have found a way to halt the progression of multiple sclerosis. The world-first [Read More]

Biogen multiple sclerosis drug Tecfidera wins European approval
Biogen multiple sclerosis drug Tecfidera wins European approval

Biogen Idec Inc’s high profile new multiple sclerosis drug Tecfidera won European approval, the company said on [Read More]

New study fuels debate about benefits of vitamin D
New study fuels debate about benefits of vitamin D

Is the vitamin D miracle just a hoax? Many scientific experts are asking that question as the number of studies casting [Read More]

Prof. Lutz Harms on the origin and treatment of MS
Prof. Lutz Harms on the origin and treatment of MS

The Berlin neurologist tells us why there is still no cure for the autoimmune disorder, and how patients can be helped [Read More]